Related Experiment Video
Updated: Jun 21, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction
Lei Zhang1, Jun Zhang, Chunqi Hu
1Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Abstract:
The tumor suppressor p53 plays a key role in the regulation of cell cycle, apoptosis, DNA repair, and senescence. It acts as a transcriptional factor, and is able to activate various genes to exert specific functions. MDM2, the main regulator of p53, inhibits the function of p53 through direct interaction. On the basis of this finding, inhibiting the MDM2-p53 interaction can be a potentially important target for cancer therapy. We showed here that L2, an analog of small-molecule MDM2 antagonist nutlins, stabilized p53 and selectively activated the p53 pathway in p53 wild-type A549 cells, resulting in a pronounced antiproliferation effect through inducing cell cycle arrest and apoptosis. Meanwhile, we confirmed by immunoprecipitation analysis that L2 could also inhibit MDM2-p53 interaction, similar to nutlin-1. Real-time PCR results revealed that L2 had no effect on the p53 gene transcriptional level, but it could induce the upregulation of p21 at the transcriptional level, which was the downstream of p53. Therefore, we concluded that the accumulation of p53 caused by L2 was mainly because of the decrease of the protein degradation rather than the elevation of p53 gene expression. Furthermore, no phosphor-p53 formed after L2 treatments, indicating that a genetoxic mechanism was unlikely to contribute to the activation of p53 by L2. In conclusion, the data acquired from A549 cells indicated that L2 exhibited high antiproliferation activity by disrupting MDM2-p53 interaction, and that the mechanism was derived from the activation of p53 and the p53 pathway. It was also surprising that L2 showed high antiproliferation effect against p53 null HL60 cells, which was quite different from nutlin-1. G2/M phase arrest might have contributed to the high antiproliferation activity of L2 on HL60 cells. The changes of p53 and MDM2 protein levels in L2-treated HL60 cells indicated that the mechanisms involved in the cell cycle arrest in A549 and HL60 cells were probably different, to which our future research would be devoted.
Insights
The novel compound L2 inhibits MDM2-p53 interaction, activating the p53 pathway and causing significant anti-proliferation effects in cancer cells. L2 demonstrates broad efficacy, even in p53-null cells, suggesting diverse therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The tumor suppressor p53 is crucial for cell cycle regulation, apoptosis, and DNA repair.
- MDM2 is the primary negative regulator of p53, inhibiting its function through direct interaction.
- Targeting the MDM2-p53 interaction is a promising strategy for cancer therapy.
Purpose of the Study:
- To investigate the effects of L2, an MDM2 antagonist analog, on p53 pathway activation and cancer cell proliferation.
- To elucidate the mechanism of L2-induced p53 stabilization and its therapeutic implications.
Main Methods:
- Treatment of p53 wild-type A549 and p53 null HL60 cells with L2.
- Immunoprecipitation assays to confirm MDM2-p53 interaction inhibition.
- Real-time PCR to assess gene transcriptional levels (p53, p21).
- Cell cycle analysis and apoptosis assays.
Main Results:
- L2 stabilized p53 and activated the p53 pathway in A549 cells, leading to cell cycle arrest and apoptosis.
- L2 inhibited the MDM2-p53 interaction and decreased p53 protein degradation, without affecting p53 gene expression.
- L2 exhibited significant antiproliferation activity against both p53 wild-type and p53 null cancer cells, with distinct mechanisms.
Conclusions:
- L2 is a potent MDM2 antagonist that effectively disrupts the MDM2-p53 interaction.
- L2 demonstrates broad-spectrum antiproliferation activity by activating p53-dependent and potentially p53-independent pathways.
- L2 represents a promising therapeutic agent for cancer treatment, warranting further investigation into its mechanisms in different cancer types.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Intrinsic Apoptotic Pathway

